Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 04 04:00PM ET
2.36
Dollar change
-0.24
Percentage change
-9.42
%
IndexRUT P/E- EPS (ttm)-0.73 Insider Own30.54% Shs Outstand62.31M Perf Week-14.98%
Market Cap147.80M Forward P/E- EPS next Y-1.65 Insider Trans0.10% Shs Float43.59M Perf Month-6.73%
Income-41.61M PEG- EPS next Q-0.16 Inst Own15.56% Short Float13.08% Perf Quarter-3.48%
Sales0.00M P/S- EPS this Y1.35% Inst Trans2.57% Short Ratio37.04 Perf Half Y-14.05%
Book/sh-1.52 P/B- EPS next Y-126.03% ROA-176.31% Short Interest5.70M Perf Year16.58%
Cash/sh0.43 P/C5.46 EPS next 5Y- ROE- 52W Range1.55 - 4.27 Perf YTD41.87%
Dividend Est.- P/FCF- EPS past 5Y-14.30% ROI-2675.95% 52W High-44.83% Beta0.71
Dividend TTM- Quick Ratio1.13 Sales past 5Y0.00% Gross Margin- 52W Low51.45% ATR (14)0.18
Dividend Ex-Date- Current Ratio1.13 EPS Y/Y TTM4.53% Oper. Margin- RSI (14)34.97 Volatility8.39% 6.92%
Employees14 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price11.00
Option/ShortYes / No LT Debt/Eq- EPS Q/Q23.30% Payout- Rel Volume3.64 Prev Close2.60
Sales Surprise- EPS Surprise10.00% Sales Q/Q- EarningsNov 14 BMO Avg Volume153.93K Price2.36
SMA20-15.35% SMA50-12.39% SMA200-10.84% Trades Volume560,287 Change-9.42%
Date Action Analyst Rating Change Price Target Change
Aug-13-20Reiterated H.C. Wainwright Buy $9 → $12
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Nov-18-24 08:00AM
Nov-14-24 08:00AM
Oct-15-24 08:00AM
Sep-30-24 08:00AM
Sep-03-24 08:30AM
08:00AM Loading…
Aug-13-24 08:00AM
Aug-01-24 08:00AM
Jun-04-24 08:00AM
May-15-24 12:53PM
08:00AM
May-13-24 08:00AM
Apr-09-24 08:00AM
Apr-05-24 08:52AM
Mar-29-24 09:11AM
08:00AM
08:00AM Loading…
Mar-12-24 08:00AM
Nov-13-23 11:11AM
08:45AM
08:00AM
Nov-03-23 08:00AM
Oct-23-23 08:00AM
Oct-12-23 08:00AM
Oct-03-23 08:00AM
Sep-26-23 08:00AM
Sep-13-23 05:22PM
Sep-11-23 09:55AM
08:00AM
Sep-07-23 12:00PM
Aug-17-23 12:00PM
Aug-14-23 08:00AM
04:37PM Loading…
May-18-23 04:37PM
May-15-23 08:00AM
Apr-27-23 08:00AM
Apr-18-23 08:00AM
Mar-30-23 08:00AM
Mar-16-23 08:00AM
Mar-02-23 08:00AM
Jan-24-23 08:00AM
Jan-05-23 08:00AM
Dec-13-22 09:55AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-14-22 08:00AM
Nov-01-22 08:00AM
Oct-14-22 08:00AM
Oct-12-22 08:00AM
Oct-06-22 08:00AM
Sep-08-22 08:00AM
Aug-15-22 08:00AM
Jul-26-22 08:00AM
Jun-21-22 08:00AM
May-23-22 08:00AM
May-16-22 08:00AM
May-11-22 11:20AM
May-03-22 08:30AM
Apr-15-22 07:20AM
Apr-14-22 08:00AM
Mar-31-22 08:00AM
Jan-06-22 08:00AM
Dec-21-21 08:00AM
Dec-13-21 08:00AM
Nov-15-21 08:00AM
Nov-05-21 04:24PM
Oct-27-21 08:00AM
Oct-05-21 03:39PM
01:55PM
Sep-21-21 08:00AM
Sep-09-21 09:00AM
Aug-30-21 08:00AM
Aug-16-21 09:00AM
Jul-30-21 04:28AM
Jul-09-21 09:25AM
08:00AM
06:29AM
Jun-13-21 11:23PM
May-17-21 08:00AM
Apr-27-21 09:28AM
Apr-19-21 08:00AM
Apr-15-21 09:00AM
Apr-14-21 08:28AM
Apr-13-21 07:01PM
Apr-06-21 08:00AM
Mar-31-21 08:00AM
Mar-08-21 08:00AM
Mar-04-21 08:00AM
Jan-31-21 02:28AM
Jan-19-21 11:15AM
Dec-11-20 08:00AM
Dec-04-20 04:17PM
Dec-01-20 08:00AM
Nov-09-20 08:00AM
Nov-02-20 08:02AM
Oct-12-20 08:11AM
Oct-06-20 03:30PM
Sep-29-20 12:00PM
08:52AM
Sep-22-20 08:04AM
Sep-10-20 08:00AM
Sep-09-20 11:46AM
Sep-02-20 08:00AM
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ELDRED KARYDirectorOct 23 '24Buy2.605001,30050,213Oct 23 01:39 PM
FREEMAN KEVIN DDirectorOct 17 '24Buy2.641,3003,43234,769Oct 17 04:03 PM
FREEMAN KEVIN DDirectorOct 16 '24Buy2.705,00013,50080,000Oct 16 04:12 PM
FREEMAN KEVIN DDirectorOct 16 '24Buy2.705,00013,50033,469Oct 16 04:12 PM
Boudes Pol FOfficerOct 04 '24Proposed Sale2.70453,7501,225,044Oct 04 04:10 PM
Zordani Richard A. Jr.DirectorAug 23 '24Buy2.301,7594,04632,083Aug 26 08:08 AM
Zordani Richard A. Jr.DirectorAug 23 '24Buy2.301,0002,3002,000Aug 26 08:08 AM
Zordani Richard A. Jr.DirectorAug 22 '24Buy2.307411,70430,324Aug 26 08:08 AM
ELDRED KARYDirectorJan 16 '24Buy2.3940095649,713Jul 23 09:38 AM
FREEMAN KEVIN DDirectorJun 20 '24Buy2.382,5005,95028,469Jun 20 01:55 PM
Zordani Richard A. Jr.DirectorApr 30 '24Buy3.521,0003,5201,000Apr 30 02:14 PM
LEWIS JOELPresident and CEOApr 24 '24Buy3.391,0003,3902,000Apr 25 01:27 PM
CZIRR JAMES C10% OwnerApr 22 '24Sale3.0621,32365,2485,925,884Apr 25 11:36 AM
CZIRR JAMES C10% OwnerApr 23 '24Sale3.063,67711,2525,922,207Apr 25 11:36 AM
FREEMAN KEVIN DDirectorApr 22 '24Buy2.982,5007,45025,969Apr 22 04:04 PM
ELDRED KARYDirectorJan 16 '24Buy1.7950089349,313Jan 16 11:23 AM